Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003010 · ClinicalTrials.gov registry record · Phase 3

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 3
Development phase
334
Enrollment target

NCT00003010: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.

NCT00003010 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 334 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003010, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
334 participants
Enrollment target

Study Summary

RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.

Interventions

  • DRUG marimastat

Trial Details

FieldValue
Enrollment Target 334 participants
Start Date 1997-12-02
Phase Phase 3
Eastern Cooperative Oncology Group

141 total trials

What the finished NCT00003010 record still lists

NCT00003010 is an interventional study that assigns participants to a tested intervention. The registered 334 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which marimastat is the first listed.

NCT00003010 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003010 about?

NCT00003010 is a clinical study titled "Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy". RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with tha...

What is the current status of trial NCT00003010?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 1997-12-02.

What interventions are being tested in trial NCT00003010?

The interventions under investigation include: marimastat (DRUG).

Who is sponsoring clinical trial NCT00003010?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003010's enrollment target sits among peer trials

334 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05131672 · 334 participants · NA

    Cast or Operation for Medial Epicondyle Fracture Treatment in Children

  • NCT05131685 · 334 participants · NA

    Distal Radius Interventions for Fracture Treatment

  • NCT05546931 · 334 participants · NA

    Mobile Health Program for Rural Hypertension

  • NCT05722197 · 334 participants · NA

    Assessment of Emotion Regulation Strategies Used When Suicidal

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00003010, the US trial registry maintained by the National Library of Medicine. NCT00003010 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.